Zacks Investment Research Lowers Grifols, S.A. (GRFS) to Hold

Grifols, S.A. (NASDAQ:GRFS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “

GRFS has been the topic of several other research reports. Bank of America Corporation reiterated a “buy” rating on shares of Grifols, in a research note on Tuesday, July 4th. Goldman Sachs Group, Inc. (The) cut shares of Grifols, from a “buy” rating to a “neutral” rating in a research note on Friday, June 30th. Finally, BidaskClub cut shares of Grifols, from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. Grifols, has an average rating of “Hold” and an average target price of $24.00.

Grifols, (NASDAQ GRFS) opened at 20.99 on Wednesday. Grifols, has a 1-year low of $14.27 and a 1-year high of $22.83. The company has a 50-day moving average price of $20.98 and a 200 day moving average price of $20.78. The stock has a market cap of $28.68 billion, a P/E ratio of 42.71 and a beta of 0.98.

WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://ledgergazette.com/2017/10/11/zacks-investment-research-lowers-grifols-s-a-grfs-to-hold.html.

Several institutional investors have recently modified their holdings of the company. Comerica Bank boosted its stake in shares of Grifols, by 1.0% during the 1st quarter. Comerica Bank now owns 18,817 shares of the biotechnology company’s stock worth $398,000 after acquiring an additional 185 shares during the last quarter. Advisor Group Inc. boosted its stake in shares of Grifols, by 2.8% during the 2nd quarter. Advisor Group Inc. now owns 11,471 shares of the biotechnology company’s stock worth $242,000 after acquiring an additional 309 shares during the last quarter. Neuberger Berman Group LLC boosted its stake in shares of Grifols, by 0.7% during the 2nd quarter. Neuberger Berman Group LLC now owns 47,530 shares of the biotechnology company’s stock worth $1,004,000 after acquiring an additional 327 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of Grifols, by 0.7% during the 2nd quarter. Bank of Montreal Can now owns 70,092 shares of the biotechnology company’s stock worth $1,480,000 after acquiring an additional 457 shares during the last quarter. Finally, Stifel Financial Corp boosted its stake in

According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “

GRFS has been the topic of several other research reports. Bank of America Corporation reiterated a “buy” rating on shares of Grifols, in a research note on Tuesday, July 4th. Goldman Sachs Group, Inc. (The) cut shares of Grifols, from a “buy” rating to a “neutral” rating in a research note on Friday, June 30th. Finally, BidaskClub cut shares of Grifols, from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. Grifols, has an average rating of “Hold” and an average target price of $24.00.

Grifols, (NASDAQ GRFS) opened at 20.99 on Wednesday. Grifols, has a 1-year low of $14.27 and a 1-year high of $22.83. The company has a 50-day moving average price of $20.98 and a 200 day moving average price of $20.78. The stock has a market cap of $28.68 billion, a P/E ratio of 42.71 and a beta of 0.98.

WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://ledgergazette.com/2017/10/11/zacks-investment-research-lowers-grifols-s-a-grfs-to-hold.html.

Several institutional investors have recently modified their holdings of the company. Comerica Bank boosted its stake in shares of Grifols, by 1.0% during the 1st quarter. Comerica Bank now owns 18,817 shares of the biotechnology company’s stock worth $398,000 after acquiring an additional 185 shares during the last quarter. Advisor Group Inc. boosted its stake in shares of Grifols, by 2.8% during the 2nd quarter. Advisor Group Inc. now owns 11,471 shares of the biotechnology company’s stock worth $242,000 after acquiring an additional 309 shares during the last quarter. Neuberger Berman Group LLC boosted its stake in shares of Grifols, by 0.7% during the 2nd quarter. Neuberger Berman Group LLC now owns 47,530 shares of the biotechnology company’s stock worth $1,004,000 after acquiring an additional 327 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of Grifols, by 0.7% during the 2nd quarter. Bank of Montreal Can now owns 70,092 shares of the biotechnology company’s stock worth $1,480,000 after acquiring an additional 457 shares during the last quarter. Finally, Stifel Financial Corp boosted its stake in shares of Grifols, by 4.3% during the 1st quarter. Stifel Financial Corp now owns 11,630 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 476 shares during the last quarter. Institutional investors and hedge funds own 21.93% of the company’s stock.

About Grifols,

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply